Hartoun Hartounian - Jun 24, 2024 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Role: EVP, Chief Operating Officer
Signature: /s/ Hartoun Hartounian
Stock symbol: BCLI
Transactions as of: Jun 24, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/25/2024, 09:04 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCLI	Common Stock	Award	$0	+30K		$0.00	30K	Jun 24, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCLI	Stock Option (Right to Buy)	Award	$0	+60K		$0.00	60K	Jun 24, 2024	Common Stock	60K	$0.38	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of restricted stock units ("RSUs") awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The RSUs will vest in full on June 24, 2025, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date.
F2	The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on June 24, 2025, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.

Content

Represents shares of restricted stock units ("RSUs") awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The RSUs will vest in full on June 24, 2025, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date.

The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on June 24, 2025, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.